Method for treating chronic myelogenous leukemia
OwnerJohn Lyonsinventor
Life of this patent
Estimating the term…
Abstract
Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.
Claims58
A treatment method comprising:
- administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.
In a treatment method for a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, the improvement comprising administering a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.
A treatment method for treating a patient having chronic myelogenous leukemia, comprising:
- administering to the patient imatinib mesylate and decitabine such that the patient's resistance to imatinib mesylate in the absence of decitabine is reduced.
A method for treating a patient having chronic myelogenous leukemia, comprising:
- administering to a patient in blast phase of chronic myelogenous leukemia a therapeutically effective amount of a DNA methylation inhibitor in combination with imatinib mesylate.
A composition comprising:
- a DNA methylation inhibitor;
- and
- imatinib mesylate.
A treatment method comprising:
- administering to a patient having chronic myelogenous leukemia and manifesting intolerance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate intolerance.
Dependencies are inferred from the claim text.